A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients with HER2- Expressing Recurrent Endometrial Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Feb 2025 Planned End Date changed from 1 Mar 2029 to 1 Aug 2029.
04 Feb 2025 Planned primary completion date changed from 1 May 2027 to 1 Oct 2027.
04 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com